Rituximab has clearly evolved as a novel therapeutic option in refractory autoimmune bullous skin disorders such as severe pemphigus vulgaris and epidermo-lysis bullosa acquisita. The mode of action suggests that not only the production of autoantibodies is inhibited by depletion of autoreactive B cells but also the critical interaction of autoreactive T and B cells, which is essential for the perpetuation of the ongoing autoimmune response. Treatment of pemphigus with rituxi-mab has been shown to be highly effective in refractory mucocutaneous pemphigus with a prolonged biological activity due to the long-term depletion of autoreactive B cells and a lack of major side effects. In addition, single case reports suggest that TNF-a blockers maybe a therapeutic option in pemphigus and mucous membrane pemphigoid with life-threatening or therapy refractory disease course, particularly as a short-term intervention therapy. However, potential side effects due to the immunosuppressive potential of TNF-antagonists such as severe bacterial infections, viral infections and tuberculosis should be carefully considered and constitute a serious hazard in patients on chronic immunosuppressive therapy.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.